Status:
TERMINATED
Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients
Lead Sponsor:
Maastricht University Medical Center
Collaborating Sponsors:
Dirinco B.V.
Conditions:
Hematological Malignancies
Bacteremia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Patients with a hematological malignancy who are undergoing intensive chemotherapy need a central venous catheter (CVC)during their treatment. CVCs are locked with heparin when they are not used. The...
Detailed Description
Central venous catheter (CVC)-related thrombosis and infections are frequently occurring complications and may cause significant morbidity in patients with hematological malignancies. Interventions to...
Eligibility Criteria
Inclusion
- patients with hematological malignancies who were going to receive a CVC for intensive chemotherapy including patients for stem cell transplantation
- written informed consent
- 18 years or older
Exclusion
- the presence of a central venous catheter at admission
- history of central venous catheter related thrombosis or infection
- indication for anticoagulant treatment or prophylaxis
- patients with totally implanted catheters
- catheters impregnated with antimicrobial agents
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
212 Patients enrolled
Trial Details
Trial ID
NCT01820962
Start Date
July 1 2006
End Date
July 1 2012
Last Update
March 29 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Atrium Medical Center Parkstad Heerlen
Heerlen, Netherlands, 6419PC
2
Maastricht University Medical Center
Maastricht, Netherlands, 6202AZ